European Commission Approves Novartis Cosentyx for Polymyalgia Rheumatica
Start here
The European Commission has approved Novartis' Cosentyx (secukinumab) for adults with polymyalgia rheumatica (PMR) who had an inadequate response to glucocorticoids or who relapsed during glucocorticoid tapering. The decision, announced by Novartis on October 21, makes Cosentyx the first IL-17A inhibitor approved for PMR anywhere in the world, giving patients with this inflammatory condition a targeted treatment option beyond glucocorticoids. Approvals in other regions, including the United States, remain pending.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickNovartis Cosentyx Approved in EU as World's First Targeted Therapy for Polymyalgia Rheumatica
On October 21, Novartis announced that the European Commission has approved Cosentyx (secukinumab) for adults with polymyalgia rheumatica (PMR) who had an inadequate response to glucocorticoids or who relapsed during glucocorticoid tapering. It is the first IL-17A inhibitor approved for PMR worldwide.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 22 17:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.